HUP0401941A3 - Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation - Google Patents

Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation

Info

Publication number
HUP0401941A3
HUP0401941A3 HU0401941A HUP0401941A HUP0401941A3 HU P0401941 A3 HUP0401941 A3 HU P0401941A3 HU 0401941 A HU0401941 A HU 0401941A HU P0401941 A HUP0401941 A HU P0401941A HU P0401941 A3 HUP0401941 A3 HU P0401941A3
Authority
HU
Hungary
Prior art keywords
antacids
inhibitor
preparation
pharmaceutical formulation
pomp
Prior art date
Application number
HU0401941A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP0401941A2 publication Critical patent/HUP0401941A2/hu
Publication of HUP0401941A3 publication Critical patent/HUP0401941A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08Oxides; Hydroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10Carbonates; Bicarbonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU0401941A 2001-07-16 2002-07-10 Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation HUP0401941A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401896 2001-07-16
PCT/SE2002/001370 WO2003007917A1 (en) 2001-07-16 2002-07-10 Pharmaceutical formulation comprising a proton pump inhibitor and antacids

Publications (2)

Publication Number Publication Date
HUP0401941A2 HUP0401941A2 (hu) 2005-01-28
HUP0401941A3 true HUP0401941A3 (en) 2008-04-28

Family

ID=8182807

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401941A HUP0401941A3 (en) 2001-07-16 2002-07-10 Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation

Country Status (24)

Country Link
US (2) US20040219211A1 (hu)
EP (1) EP1416922A1 (hu)
JP (1) JP2004536855A (hu)
KR (1) KR20040018463A (hu)
CN (1) CN100469366C (hu)
AR (1) AR034757A1 (hu)
AU (1) AU2002316020B2 (hu)
BG (1) BG108515A (hu)
BR (1) BR0211117A (hu)
CA (1) CA2453290A1 (hu)
CO (1) CO5550417A2 (hu)
HU (1) HUP0401941A3 (hu)
IL (1) IL159584A0 (hu)
IS (1) IS7111A (hu)
MX (1) MXPA04000385A (hu)
MY (1) MY136137A (hu)
NO (1) NO20040178L (hu)
NZ (1) NZ530511A (hu)
PL (1) PL367686A1 (hu)
RU (1) RU2301662C2 (hu)
UA (1) UA75673C2 (hu)
UY (1) UY27385A1 (hu)
WO (1) WO2003007917A1 (hu)
ZA (1) ZA200400285B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446759A1 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
CN100438914C (zh) * 2003-10-15 2008-12-03 富士化学工业株式会社 用于口腔内快速崩解的片剂的组合物
WO2005044223A1 (en) * 2003-11-07 2005-05-19 Takeda Pharmaceutical Company Limited Chewable tablet
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP1621187A1 (en) * 2004-07-26 2006-02-01 AstraZeneca AB Pharmaceutical multiparticulate tablet formulations and process for their preparation
US8057820B2 (en) 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术(石家庄)有限公司 一种奥美拉唑组合物及其制备方法
CA2711475A1 (en) * 2008-01-10 2009-07-16 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
BRPI0822140A8 (pt) 2008-01-10 2022-07-05 Evonik Roehm Gmbh Preparação farmacêutica ou nutracêutica revestida tendo liberação pulsada de subsatância ativa
WO2009112156A1 (en) * 2008-03-10 2009-09-17 Bayer Consumer Care Ag Palatable solid composition comprising antacid and saliva stimulant
PE20141034A1 (es) * 2008-03-11 2014-09-10 Takeda Pharmaceutical Preparacion solida de desintegracion oral
BRPI0921599B8 (pt) * 2008-11-17 2021-05-25 Nycomed Pharma As método para a preparação de um comprimido, e, comprimido de carbonato de cálcio
SG190717A1 (en) * 2010-12-03 2013-07-31 Takeda Pharmaceutical Orally disintegrating tablet
CN102085188B (zh) * 2011-01-14 2013-01-02 寿光富康制药有限公司 一种兰索拉唑肠溶微丸的制备方法
CN102078616A (zh) * 2011-01-28 2011-06-01 北京虹湾医药技术有限公司 埃索美拉唑碳酸氢钠组合物
US8277842B1 (en) * 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
CN102631327B (zh) * 2012-05-14 2013-08-28 海南葫芦娃制药有限公司 一种奥美拉唑肠溶微丸及其制备方法
CN103479593B (zh) * 2013-05-10 2014-10-08 青岛双鲸药业有限公司 一种奥美拉唑肠溶片的制备方法
JP6156037B2 (ja) * 2013-10-03 2017-07-05 ライオン株式会社 固形医薬製剤組成物
CN103784414B (zh) * 2013-12-18 2018-01-30 北京华禧联合科技发展有限公司 一种埃索美拉唑肠溶片及其制备方法
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
KR20180103940A (ko) * 2016-02-03 2018-09-19 노파르티스 아게 유기 화합물의 갈레닉(Galenic) 제제
SG11201809555QA (en) * 2016-04-29 2018-11-29 Alan Thompson Veterinary composition
US10076494B2 (en) * 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108434117A (zh) * 2018-03-29 2018-08-24 成都通德药业有限公司 一种奥美拉唑肠溶胶囊的制备方法
RU2727506C1 (ru) * 2019-09-09 2020-07-22 Пивипи Лабс Пте. Лтд. Средство для лечения эректильной дисфункции
CN114980867B (zh) * 2020-01-23 2024-03-15 韩美药品株式会社 包含质子泵抑制剂和抗酸剂的药物复合制剂
WO2022103233A1 (ko) * 2020-11-13 2022-05-19 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN114617852B (zh) * 2020-12-10 2023-06-27 昆药集团股份有限公司 一种奥美拉唑肠溶制剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2516408B2 (ja) * 1988-08-18 1996-07-24 エスエス製薬株式会社 被覆顆粒を含む錠剤
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
DE19617487A1 (de) * 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
JP3961596B2 (ja) * 1996-10-15 2007-08-22 富士化学工業株式会社 無機制酸剤含有速分散性造粒物、その製造方法及び用時懸濁内服制酸剤
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
KR100412327B1 (ko) * 1997-07-01 2003-12-31 화이자 인코포레이티드 서트랄린 염 및 서트랄린의 서방성 투여형
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
DK1736144T3 (en) * 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
EP1203580A4 (en) * 1999-06-18 2004-06-30 Takeda Chemical Industries Ltd SOLID PREPARATIONS WITH FAST DISINTEGRATION
DE19954653B4 (de) * 1999-11-13 2006-01-19 Contitech Profile Gmbh Extruder zur Aufbereitung von Kautschukmischungen
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
KR20030072555A (ko) * 2000-12-07 2003-09-15 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 신속 붕해 정제

Also Published As

Publication number Publication date
IL159584A0 (en) 2004-06-01
MY136137A (en) 2008-08-29
AU2002316020B2 (en) 2007-03-15
RU2301662C2 (ru) 2007-06-27
CO5550417A2 (es) 2005-08-31
ZA200400285B (en) 2005-06-29
BG108515A (en) 2005-02-28
WO2003007917A1 (en) 2003-01-30
MXPA04000385A (es) 2004-05-04
UA75673C2 (en) 2006-05-15
JP2004536855A (ja) 2004-12-09
NZ530511A (en) 2005-06-24
KR20040018463A (ko) 2004-03-03
UY27385A1 (es) 2003-02-28
CN1555256A (zh) 2004-12-15
NO20040178L (no) 2004-03-16
HUP0401941A2 (hu) 2005-01-28
US20040219211A1 (en) 2004-11-04
RU2004101061A (ru) 2005-04-20
PL367686A1 (en) 2005-03-07
BR0211117A (pt) 2004-06-22
CA2453290A1 (en) 2003-01-30
IS7111A (is) 2004-01-15
EP1416922A1 (en) 2004-05-12
AR034757A1 (es) 2004-03-17
US20110135722A1 (en) 2011-06-09
CN100469366C (zh) 2009-03-18

Similar Documents

Publication Publication Date Title
HUP0401941A3 (en) Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation
HUP0302857A3 (en) Pharmaceutical formulation
TWI340034B (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
HUP0303434A3 (en) Atorvastatin calcium in a pharmaceutical form, composition thereof, and pharmaceutical formulation comprising atorvastatin calcium
HUP0302847A3 (en) Pharmaceutical formulation comprising bicalutamide
AU2002232492A1 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
GB0118689D0 (en) Pharmaceutical formulation
AU2002257582A1 (en) Pharmaceutical formulation
PL366432A1 (en) Pharmaceutical formulation
HUP0500638A3 (en) Flashmelt oral dosage formulation
GB0322868D0 (en) A novel catalytic formulation and its preparation technical field
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
GB0104749D0 (en) Pharmaceutical formulation
GB0014849D0 (en) Pharmaceutical aerosol formulation
AU2002238748A1 (en) Pharmaceutical aerosol formulation
EP1414417A4 (en) PHARMACEUTICAL FORMULATION
GB0128335D0 (en) Pharmaceutical aerosol formulation
GB0106018D0 (en) Pharmaceutical aerosol formulation
GB0124712D0 (en) Pharmaceutical formulation
AU2002235072A1 (en) Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
GB0014424D0 (en) Pharmaceutical formulation
GB0018654D0 (en) Pharmaceutical formulation
GB0018686D0 (en) Pharmaceutical formulation
GB0014451D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees